Jennifer Rowell, MD
Endocrinology, Diabetes & Metabolism · Durham, NCNPI 1093928376
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,552 of the $2,843 with a category attached, or 89.8%. Eli Lilly accounts for 94.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $2,711 and has fallen 95.8% since, to $113 in 2024.
Across 15 payments — averaging $189.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3K
- Corcept Therapeutics$113
- Merck$20
- Regeneron Healthcare Solutions, Inc.$19
Across 16 payments — averaging $39,253 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$619K
- Xeris Pharmaceuticals, Inc.$9K
What the payments were for
- Travel & lodging$2,55290%
- Food & beverage$2539%
- Education$391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 12 | $2,692 |
| Corcept Therapeutics | 1 | $113 |
| Merck | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$113
How this compares
$2,843 in reported general payments places this provider in the 60th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 12 | $126,623 |
| MounjaroTirzepatide | 86 | $123,654 |
| OzempicSemaglutide | 35 | $48,462 |
| JardianceEmpagliflozin | 21 | $26,285 |
| TrulicityDulaglutide | 21 | $24,465 |
| Repatha SureclickEvolocumab | 30 | $21,782 |
| Praluent PenAlirocumab | 13 | $16,246 |
| SynthroidLevothyroxine Sodium | 91 | $7,824 |
| Humalog Kwikpen U-100Insulin Lispro | 25 | $6,089 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $5,957 |
| Novolog FlexpenInsulin Aspart | 13 | $5,764 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,556 |
| BaqsimiGlucagon | 12 | $5,303 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $4,062 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 20 | $3,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $113 | $126,62312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Durham
- Jennifer GreenDurham$439K
- Todd FriezeDurham$421K
- David D AlessioDurham$212K
- Thomas WeberDurham$16K
- Leena ShahlaDurham$14K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.